当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Gizem Kececi Ozgur
This Center for International Blood and Marrow Transplant Research report describes the use of hematopoietic stem cell transplantation (HSCT) in pediatric cases with cancer, 4408 witnessing allogeneic (allo) and3076 witnessing autologous (bus) HSCT in the United States between 2008 and 2014. Leukemia was the most common suggestion for an allo- transplant (n = 4170; 94), and among these, acute lymphoblastic leukemia in alternate complete absolution (n = 829; 20) and acute myeloid leukemia in first complete absolution (n = 800; 19) werethe most common. The most constantly used patron relation, stem cell sources, and HLA match were unconnected patron (n = 2933; 67), bone gist (n = 2378; 54), and matched at8/8 HLA antigens (n = 1098; 37) independently. Neuroblastoma was the most common primary lump for a bus- transplant (n = 1338; 44). Tandem bus- transplants for neuroblastoma declined after 2012(40 in 2011, 25 in 2012, and 8 in 2014), whereas tandem bus- transplants increased for brain excrescences (57 in 2008 and 77 in 2014). Allo- transplants from cousins other than HLA-identical siblings doubled between 2008 and 2014 (3 in 2008 and 6 in 2014). These trends will be covered in unborn reports of transplant practices in the United States.